Sidi A Bencherif

20110111035, May 12, 2011

Aug 15, 2008

12/673583

Newell R. Washburn - Pittsburgh PA, US
Sidi Ahmed Bencherif - Boston MA, US
Liang Tso Sun - Pittsburgh PA, US

A61K 9/00
A61K 38/02
C08B 15/00
C08B 37/08
C07K 16/18
C07K 16/24
A61K 31/717
A61K 31/728
A61K 39/395
A61P 29/00
A61P 17/02
A61P 19/02

424488, 514 191, 536 56, 536 53, 5303911, 514 57, 514 54, 4241781

The various embodiments provide a composition that provides local control over inflammation. The composition localizes the activities of the cytokine-neutralizing antibodies to the site of inflammation through covalent attachment to hydrophilic matrices. The various embodiments including a hydrophilic polymer, a ligand binding moiety covalently attached to the polymer, and optionally, a cellular adhesion peptide covalently attached to the polymer. The hydrophilic polymer may be a glycosaminoglycan such as hyaluronan. The cellular adhesion peptide may be a linear RGD peptide sequence covalently attached to the polymer. The ligand binding moiety may be a monoclonal antibody covalently attached to the polymer. The antibody may be selected from the group consisting of an anti-IL-1β, an anti-IL-6, an anti-TNF-α, and combinations thereof. The polymer functions as a substrate or matrix for cell migration and tissue regeneration. The RGD peptide functions to promote cellular proliferation, migration and attachment to the polymer. The monoclonal antibody functions to inhibit the inflammatory response.

20130344129, Dec 26, 2013

Aug 17, 2013

13/969515

Sidi Ahmed BENCHERIF - Boston MA, US
Liang Tso SUN - Pittsburgh PA, US

CARNEGIE MELLON UNIVERSITY - Pittsburgh PA

A61K 39/395

424445, 4241451

The various embodiments provide a composition that provides local control over inflammation. The composition localizes the activities of the cytokine-neutralizing antibodies to the site of inflammation through covalent attachment to hydrophilic matrices. The various embodiments including a hydrophilic polymer, a ligand binding moiety covalently attached to the polymer, and optionally, a cellular adhesion peptide covalently attached to the polymer. The hydrophilic polymer may be a glycosaminoglycan such as hyaluronan. The cellular adhesion peptide may be linear RGD peptide sequence covalently attached to the polymer. The ligand binding moiety may be a monoclonal antibody covalently attached to the polymer. The antibody may be selected from the group consisting of an anti-IL-1β, an anti-IL-6, an anti-TNF-α, and combinations thereof. The polymer functions as a substrate or matrix for cell migration and tissue regeneration. The RGD peptide functions to promote cellular proliferation, migration and attachment to the polymer. The monoclonal antibody functions to inhibit the inflammatory response.

20220211912, Jul 7, 2022

May 9, 2020

17/595139

Sherif Soliman - Irvine CA, US
Oussama Boundaoui - Bridgeview IL, US
Hamzah Khalaf - Helotes TX, US
Sidi A. Bencherif - East Boston MA, US

A61L 27/52
A61L 27/54
A61L 27/58
A61L 27/38
A61L 27/20
C08L 5/04

A hydrogel retinal tamponade agent is disclosed herein. The disclosed hydrogel tamponade agent acts as a temporary barrier to fluid flow into the subretinal space and obviates the need to use intraocular gases or silicone oil as a retinal tamponade agent in a retinal detachment repair procedure. The hydrogel tamponade agent remains in place after a permanent seal is achieved and is slowly resorbed. The hydrogel tamponade agent is preferably biocompatible.

20210308334, Oct 7, 2021

Aug 8, 2019

17/266351

- Boston MA, US
Sidi A. Bencherif - Boston MA, US
Michail Sitkovsky - Boston MA, US
Thibault Colombani - Boston MA, US
Stephen Hatfield - Peabody MA, US

A61L 27/54
A61L 27/52
A61L 27/02
A61L 27/20

Disclosed are nanocomposite oxygen-generating cryogels and their uses in reducing hypoxia in a biological tissue, such as a tumor. Methods of treating cancer with the disclosed cryogels are also provided.

20210121603, Apr 29, 2021

Oct 26, 2020

17/080336

- Boston MA, US
Sidi A. Bencherif - Boston MA, US
Nasim Annabi - Los Angeles CA, US

A61L 27/26
A61K 35/15
A61L 27/52
A61K 47/36
A61K 47/32
A61K 47/58

Disclosed herein are functionalized dopamine derivatives comprising an optionally substituted acrylic acid moiety and optionally a polyethylene glycol linking moiety. The functionalized dopamine derivatives are useful in cryogel formulations to improve the adhesivity of the cryogel, while preventing undesirable oxidation typically associated with dopamine-containing hydrogels and cryogels. Properties such as cryogel adhesivity, pore size, and interconnectivity are tunable features. Also provided herein are methods of treating a wound or promoting tissue regeneration with a cryogel of the invention or a formulation comprising such a cryogel.

20200284730, Sep 10, 2020

Mar 6, 2020

16/811785

- Boston MA, US
Qingxuan Li - Boston MA, US
Liyuan Ma - Newton MA, US
Sidi A. Bencherif - Boston MA, US
Thibault Colombani - Boston MA, US

G01N 21/64
C12M 1/34
G01N 27/02

Disclosed is a technology for assaying individual cells, in which the identity of each individual cell in an ordered array is determined from coordinates assigned to it, and can be readout at high throughput with microscope. The method is able to test responses of millions of identical cells in multiple chemical and physical processes with superior statistics power to facilitate deep data mining.

20190343979, Nov 14, 2019

Jul 9, 2019

16/505910

- Cambridge MA, US
- Boston MA, US
David J. Mooney - Sudbury MA, US
Aristidis Veves - Quincy MA, US
Thomas Michael Braschler - Quincy MA, US
Sidi A. Bencherif - Dorchester MA, US

A61L 15/28
A61L 15/44
A61K 38/04
A61L 15/42

The invention provides a solution to the drawbacks associated with conventional alginate dressings. This invention features improved alginate dressings or bandages as well as a fabrication process that results in an alginate sheet that is preloaded with drug, can be stored in a freeze-dried state, and is compliant and ready to use at the time of administration.

20180333513, Nov 22, 2018

Jun 8, 2018

16/003192

- Cambridge MA, US
- Boston MA, US
David J. Mooney - Sudbury MA, US
Aristidis Veves - Quincy MA, US
Thomas Michael Braschler - Quincy MA, US
Sidi A. Bencherif - Dorchester MA, US

A61L 15/28
A61L 15/44
A61K 38/04
A61L 15/42

The invention provides a solution to the drawbacks associated with conventional alginate dressings. This invention features improved alginate dressings or bandages as well as a fabrication process that results in an alginate sheet that is preloaded with drug, can be stored in a freeze-dried state, and is compliant and ready to use at the time of administration.